We found that serine synthesis pathway (SSP) and cardiolipin synthesis are metabolic vulnerabilities of sorafenib‐resistant and hypoxic HCC cells, respectively.[19, 20] Therapeutically, targeting the first committed enzyme of the SSP, phosphoglycerate dehydrogenase (PHGDH), sensitized HCC cells to sorafenib treatment[19] while targeting protein‐tyrosine phosphatase mitochondrial 1 (PTPMT1), the rate‐limiting enzyme in the cardiolipin synthesis pathway sensitized hypoxic HCC cells to cell death. The gene discussed is PTPMT1; the disease is hepatocellular carcinoma.